BeyondSpring
  • About
    • Who We Are
    • Management Team
    • Scientific Advisors
    • Board of Directors
  • Pipeline & Research
    • Pipeline
    • Plinabulin
    • Protein Degradation
    • Other Pipeline
    • Posters & Publications
    • Collaborations
    • Expanded Access Policy
  • NEWS & MEDIA
  • Investors
    • Stock Overview
    • Events & Presentations
    • Financials & Filings
    • ESG
    • Corporate Governance
  • Careers
  • Contact Us
Select Page

Society for Immunotherapy of Cancer (SITC) Annual Meeting (2019)

July 14, 2020

11.09.2019

Society for Immunotherapy of Cancer (SITC) Annual Meeting (2019)

Validation of a Single-Blinded (Patients Only) Study Design for the Prevention of Premature Patient Consent Withdrawal in the Immuno-Oncology Trial DUBLIN-3

RECENT NEWS ARTICLES

  • BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
  • BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
  • BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
  • BeyondSpring Files 2024 Annual Report on Form 10-K
  • BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
  • BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
  • BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
  • BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
  • BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
  • BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine

RECENT MEDIA COVERAGE

  • Seeking Alpha: BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC
  • Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC
  • IO360: Developing a Molecule to Help Patients Respond to Immunotherapy
  • TD Ameritrade Watch List
  • Managing Chemotherapy Toxicities for Improved Patient Outcomes
  • New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
  • Seed Therapeutics blossoms in an $800M deal with Lilly
  • Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
  • BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
  • JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
Investor Contact
IR@beyondspringpharma.com
Media Contact
PR@beyondspringpharma.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

ABOUT

  • Who We Are
  • Management Team
  • Scientific Advisors
  • Board of Directors

PIPELINE & RESEARCH

  • Pipeline Overview
  • Plinabulin
  • Protein Degradation
  • Other Pipeline
  • Posters & Publications
  • Collaboration
  • Expanded Access Policy

INVESTORS

  • Stock Overview
  • Events & Presentations
  • Financials & Filings
  • Corporate Governance

CAREERS

  • Job Opportunities

NEWS & MEDIA

  • Press Releases
  • Media Coverage
BeyondSprings Inc LinkedIn   BeyondSprings Inc Twitter

BeyondSprings Inc LinkedIn      BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved.   Privacy Notice   |   Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.OkPrivacy policy